Nathalie Moll shares her views on the pharma industry’s response to COVID-19 and Europe’s preparedness for future health crises. She also discusses the reach and ambition of the Pharma Strategy and addresses the issues around equitable access.

"The pandemic was an intense microcosm of some of our wider healthcare challenges and focused attention on areas that can be improved. There is a need to look for longer-term health outcomes, focus on early care prevention, digitalization, telemedicine and new payment models."